A multicentre phase II trial to determine the efficacy of RAD 001 (everolimus, Afinitor) as second line therapy in patients with transitional cell carcinoma (TCC) of the urothelium which failed or progressed after first line chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 17 May 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- Acronyms AFINIVEST
- 02 Jun 2015 Primary endpoint (Progression-free survival rate) has been met, according to abstract presented at ASCO 2015.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO 2015).
- 02 Jun 2015 Status changed from recruiting to completed, as reported in ASCO 2015 abstract.